医访谈丨妥善管理副作用,取得比89.6个月更长生存的可能
第二代ALK抑制剂
让肺癌患者有可能实现长期生存
选择治疗药物的三大关注:
效果、药物经济学价值,以及副作用
妥善管理副作用,
获得更长生存的可能
免
责
声
明
“本资料目的在于为公众提供疾病领域相关知识、提高其对于疾病认知水平,并非以任何方式实现推荐或推广相关产品或服务的目的;本资料中所涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见与指导。”



参考资料:
[1]、J Davies, M Martinec, M Coudert, P Delmar, U Becker, G Crane,PCN313 - Real World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences and Survival of ALK-Inhibitor Treated Patients,Value in Health,Volume 19, Issue 7,2016,Page A765,ISSN 1098-3015,
[2]、Tomasini, Pascale, et al. “Alectinib in the Treatment of ALK-Positive Metastatic Non-Small Cell Lung Cancer: Clinical Trial Evidence and Experience with a Focus on Brain Metastases.” Therapeutic Advances in Respiratory Disease, Jan. 2019, doi:10.1177/1753466619831906.
[3]、Duruisseaux, Michaël et al. “Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.” Oncotarget vol. 8,13 (2017): 21903-21917. doi:10.18632/oncotarget.15746
[4]、Zhang, I, Zaorsky, NG, Palmer, JD. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 2015; 16: e510–e521.
[5]、Griesinger F, Roeper J, Pöttgen C, Willborn KC, Eberhardt WEE. Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. Oncotarget. 2018;9(80):35181–35194. Published 2018 Oct 12. doi:10.18632/oncotarget.26073
[6]、ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)Cho, Byoung Chul et al.Journal of Thoracic Oncology, Volume 12, Issue 9, 1357 - 1367
[7]、Chul Cho, Byoung & Kim, Dong-Wan & Bearz, Alessandra & A. Laurie, Scott & Mckeage, Mark & Borra, Gloria & Park, Keunchil & Kim, Sang-We & Ghosn, Marwan & Ardizzoni, Andrea & Maiello, Evaristo & Greystoke, Alastair & Yu, Richard & Osborne, Karen & Gu, Wen & W. Scott, Jeffrey & Q. Passos, Vanessa & Lau, Yvonne & Wrona, Anna. (2017). ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12. 10.1016/j.jtho.2017.07.005.
[8]、塞瑞替尼说明书
